Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12011124rdf:typepubmed:Citationlld:pubmed
pubmed-article:12011124lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12011124lifeskim:mentionsumls-concept:C1332225lld:lifeskim
pubmed-article:12011124lifeskim:mentionsumls-concept:C1328050lld:lifeskim
pubmed-article:12011124pubmed:issue10lld:pubmed
pubmed-article:12011124pubmed:dateCreated2002-5-15lld:pubmed
pubmed-article:12011124pubmed:abstractTextRandomized trial LNH93-3 was conducted on patients who had poor-prognosis aggressive lymphoma and were younger than 60 years with two to three factors of the age-adjusted International Prognostic Index to evaluate the benefit of early high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT).lld:pubmed
pubmed-article:12011124pubmed:languageenglld:pubmed
pubmed-article:12011124pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12011124pubmed:citationSubsetIMlld:pubmed
pubmed-article:12011124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12011124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12011124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12011124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12011124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12011124pubmed:statusMEDLINElld:pubmed
pubmed-article:12011124pubmed:monthMaylld:pubmed
pubmed-article:12011124pubmed:issn0732-183Xlld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:Groupe...lld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:HermineOlivie...lld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:LederlinPierr...lld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:FilletGeorges...lld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:CoiffierBertr...lld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:LepageEricElld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:TillyHervéHlld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:GisselbrechtC...lld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:QuesnelBrunoBlld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:MolinaThierry...lld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:GabarreJeanJlld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:GuilminFranco...lld:pubmed
pubmed-article:12011124pubmed:authorpubmed-author:ReyesFélixFlld:pubmed
pubmed-article:12011124pubmed:issnTypePrintlld:pubmed
pubmed-article:12011124pubmed:day15lld:pubmed
pubmed-article:12011124pubmed:volume20lld:pubmed
pubmed-article:12011124pubmed:ownerNLMlld:pubmed
pubmed-article:12011124pubmed:authorsCompleteYlld:pubmed
pubmed-article:12011124pubmed:pagination2472-9lld:pubmed
pubmed-article:12011124pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:meshHeadingpubmed-meshheading:12011124...lld:pubmed
pubmed-article:12011124pubmed:year2002lld:pubmed
pubmed-article:12011124pubmed:articleTitleShortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.lld:pubmed
pubmed-article:12011124pubmed:affiliationInstitut d'Hématologie, GELA Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris cedex 10, France. christian.gisselbrecht@sls.ap-hop-paris.frlld:pubmed
pubmed-article:12011124pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12011124pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12011124pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12011124pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12011124pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12011124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12011124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12011124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12011124lld:pubmed